13/05/2026 22:10
|
Medical, Health & Aged Care
First-in-human study evaluates weekly IV Sapu003 in advanced mTOR-sensitive solid tumors, including HR+/HER2- breast cancer, RCC, NETs, TSC-associated tumors, and HCC
SAN DIEGO, Calif., May 13,...